AVITA Medical to Host Investor Webinar Briefing
AVITA Medical (NASDAQ: RCEL, ASX: AVH), a therapeutic acute wound care company, has announced an upcoming investor webinar briefing scheduled for February 18, 2025, at 2:00 p.m. Pacific Standard Time (February 19, 2025, at 9:00 a.m. Australian Eastern Daylight Time).
The presentation will be led by CEO Jim Corbett and CFO David O'Toole, focusing on the company's financial and business results from their recent fourth quarter and full-year 2024 earnings webcast. The event will include a Q&A session, with participants able to submit questions through the registration page.
Interested shareholders and prospective investors can register for the webinar via a provided Zoom link. A replay of the presentation will be made available on the AVITA Medical investor relations website.
AVITA Medical (NASDAQ: RCEL, ASX: AVH), un'azienda specializzata nella cura terapeutica delle ferite acute, ha annunciato un prossimo webinar per gli investitori, programmato per il 18 febbraio 2025, alle 14:00 ora standard del Pacifico (il 19 febbraio 2025, alle 9:00 ora legale orientale australiana).
La presentazione sarà condotta dal CEO Jim Corbett e dal CFO David O'Toole, con un focus sui risultati finanziari e aziendali del quarto trimestre e dell'intero anno 2024, presentati durante il webcast sugli utili. L'evento includerà una sessione di domande e risposte, con i partecipanti che potranno inviare domande tramite la pagina di registrazione.
Gli azionisti interessati e i potenziali investitori possono registrarsi per il webinar tramite un link Zoom fornito. Una registrazione della presentazione sarà disponibile sul sito web delle relazioni con gli investitori di AVITA Medical.
AVITA Medical (NASDAQ: RCEL, ASX: AVH), una empresa dedicada al cuidado terapéutico de heridas agudas, ha anunciado un próximo seminario web para inversores programado para el 18 de febrero de 2025, a las 2:00 p.m. hora estándar del Pacífico (19 de febrero de 2025, a las 9:00 a.m. hora de verano del este australiano).
La presentación será liderada por el CEO Jim Corbett y el CFO David O'Toole, centrándose en los resultados financieros y comerciales de la compañía del cuarto trimestre y del año completo 2024, presentados en su webcast de ganancias. El evento incluirá una sesión de preguntas y respuestas, donde los participantes podrán enviar preguntas a través de la página de registro.
Los accionistas interesados y los posibles inversores pueden registrarse para el seminario web a través de un enlace de Zoom proporcionado. Se hará disponible una repetición de la presentación en el sitio web de relaciones con inversores de AVITA Medical.
AVITA Medical (NASDAQ: RCEL, ASX: AVH), 급성 상처 치료 전문 회사가 2025년 2월 18일 오후 2시 태평양 표준시 (2025년 2월 19일 오전 9시 호주 동부 일광 절약 시간)에 예정된 투자자 웨비나 브리핑을 발표했습니다.
발표는 CEO 짐 코르벳과 CFO 데이비드 오툴이 주도하며, 최근 2024년 4분기 및 연간 실적 웹캐스트에서 회사의 재무 및 비즈니스 결과에 중점을 둡니다. 이 행사에는 질문 및 답변 세션이 포함되어 있으며, 참가자는 등록 페이지를 통해 질문을 제출할 수 있습니다.
관심 있는 주주 및 잠재적 투자자는 제공된 Zoom 링크를 통해 웨비나에 등록할 수 있습니다. 발표의 재생은 AVITA Medical 투자자 관계 웹사이트에서 제공될 것입니다.
AVITA Medical (NASDAQ: RCEL, ASX: AVH), une entreprise spécialisée dans les soins thérapeutiques des plaies aiguës, a annoncé un prochain webinaire pour investisseurs prévu pour le 18 février 2025 à 14h00, heure normale du Pacifique (19 février 2025 à 9h00, heure d'été de l'Est australien).
La présentation sera animée par le PDG Jim Corbett et le CFO David O'Toole, se concentrant sur les résultats financiers et commerciaux de l'entreprise pour le quatrième trimestre et l'année complète 2024, présentés lors de leur webdiffusion sur les bénéfices. L'événement comprendra une session de questions-réponses, où les participants pourront soumettre des questions via la page d'inscription.
Les actionnaires intéressés et les investisseurs potentiels peuvent s'inscrire au webinaire via un lien Zoom fourni. Un enregistrement de la présentation sera disponible sur le site Web des relations avec les investisseurs d'AVITA Medical.
AVITA Medical (NASDAQ: RCEL, ASX: AVH), ein Unternehmen für therapeutische Akutwundversorgung, hat ein bevorstehendes Investor-Webinar angekündigt, das für den 18. Februar 2025 um 14:00 Uhr Pazifische Standardzeit (19. Februar 2025 um 9:00 Uhr Australische Ost-Daylight-Zeit) geplant ist.
Die Präsentation wird von CEO Jim Corbett und CFO David O'Toole geleitet und konzentriert sich auf die finanziellen und geschäftlichen Ergebnisse des Unternehmens aus ihrem jüngsten vierten Quartal und dem Gesamtjahr 2024 Earnings-Webcast. Die Veranstaltung wird eine Frage- und Antwortsitzung beinhalten, bei der die Teilnehmer Fragen über die Registrierungsseite einreichen können.
Interessierte Aktionäre und potenzielle Investoren können sich über einen bereitgestellten Zoom-Link für das Webinar registrieren. Eine Wiederholung der Präsentation wird auf der Investor-Relations-Website von AVITA Medical verfügbar sein.
- None.
- None.
VALENCIA, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O’Toole, Chief Financial Officer, on February 18, 2025, at 2:00 p.m. Pacific Standard Time (February 19, 2025, at 9:00 a.m. Australian Eastern Daylight Time).
The webinar presentation will cover financial and business results from our recent fourth quarter and full-year 2024 earnings webcast and will conclude with a Q&A session. Participants are invited to submit their questions via the registration page.
To register for the presentation, please follow this Zoom link:
https://us02web.zoom.us/webinar/register/WN_Nx3kCIIOSmOj686nctwpRA.
A replay will be available on the AVITA Medical website, ir.avitamedical.com, following the presentation.
About AVITA Medical, Inc.
AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™ Cells, offering a groundbreaking solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to market, sell, and distribute Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm®, a biosynthetic wound matrix.
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns and full-thickness skin defects. The RECELL System, excluding RECELL GO®, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.
To learn more, visit www.avitamedical.com.
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
FAQ
When is AVITA Medical (RCEL) hosting its investor webinar for Q4 and FY2024 results?
What topics will be covered in AVITA Medical's (RCEL) February 2025 investor webinar?
How can investors participate in AVITA Medical's (RCEL) February 2025 webinar?
Where can investors access the replay of AVITA Medical's (RCEL) February 2025 webinar?
